ABBV - AbbVie Inc.
| Previous Close | 86.70 |
| Open | 86.76 |
| Bid | 87.02 x 800 |
| Ask | 87.05 x 800 |
| Day's Range | 86.78 - 87.28 |
| 52 Week Range | 62.66 - 92.99 |
| Volume | 549,460 |
| Avg. Volume | 7,595,089 |
| Market Cap | 129B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | 39.94 |
| EPS (TTM) | 2.18 |
| Earnings Date | Jan 23, 2020 - Jan 27, 2020 |
| Forward Dividend & Yield | 4.72 (5.45%) |
| Ex-Dividend Date | 2020-01-14 |
| 1y Target Est | 95.00 |
- Simply Wall St.
Should We Worry About AbbVie Inc.'s (NYSE:ABBV) P/E Ratio?
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
- Zacks
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
- Zacks
Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
- Zacks
Top Research Reports for Novartis, AbbVie & Sanofi
Top Research Reports for Novartis, AbbVie & Sanofi
- Zacks
Biotech ETFs Hit New Highs on Deal Activities
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
- Investor's Business Daily
Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?
Merck stock is on an upswing with a 14% gain in the first 11 full months of 2019. Meanwhile shares of other pharma companies grabbed a smaller gain. Is it time to give MRK stock a shot?
- Zacks
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $86.43, marking a -0.63% move from the previous day.
- Zacks
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
- American City Business Journals
World's largest biotech company to move up to BioMed's big South City project
The biotech company acquired its first Bay Area presence 15 years ago; now it's planning to move into a high-profile biotech-focused project.
- Zacks
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
- Zacks
3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
- GlobeNewswire
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.
- PR Newswire
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.
- PR Newswire
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combination with rituximab (VenR) in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). The updated data from the Phase 3 MURANO trial four-year analysis (median follow-up of 48 months with all patients off VENCLEXTA/VENCLYXTO treatment for a median of 22 months) showed that patients with R/R CLL who completed the chemotherapy-free, two-year fixed duration course of VENCLEXTA/VENCLYXTO treatment combination maintained progression-free survival (PFS) and overall survival (OS). Patients who completed treatment with the VENCLEXTA/VENCLYXTO combination also achieved higher rates of minimal residual disease (MRD)-negativity and complete remissions compared to those treated with a standard of care, bendamustine plus rituximab (BR).1 The full results were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (abstract 355).
- PR Newswire
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA® (ibrutinib) monotherapy compared to later lines of therapy (LOT) extended progression-free survival (PFS) and increased the likelihood of a complete response (CR) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) – demonstrating that some patients achieved a disappearance of any signs of disease.
- PR Newswire
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), which is part of the National Institutes of Health. Study results showed superior progression-free survival (PFS) and overall survival (OS) in patients with chronic lymphocytic leukemia (CLL) new to treatment.
- PR Newswire
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial,1 evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Results showed that patients who received up to 12 cycles of the combination regimen achieved high rates of undetectable minimal residual disease (uMRD) in both peripheral blood (PB; 75 percent of patients) and in bone marrow (BM; 72 percent of patients). Safety data were consistent with the known safety profiles of IMBRUVICA and VENCLEXTA/VENCLYXTO used as individual therapies.
- GlobeNewswire
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported safety and biomarker data from the single ascending dose (SAD) phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) meeting being held December 4-6 in San Diego, California.
- Reuters
Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial
UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease. UCB's drug, bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company. AbbVie's Humira is the world's top selling drug and treats rheumatoid arthritis and psoriasis.
CNW GroupAbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis
- Zacks
J&J Stock Witnesses Volatility in '19: What to Expect in 2020
Here we discuss the ups and downs of J&J's (JNJ) stock this year.
- Investor's Business Daily
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
- Investopedia
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
- TheStreet.com
[video]AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug
AbbVie's fledgling rheumatoid arthritis treatment Rinvoq is showing promise and appears to be tracking "meaningfully ahead of expectations," according to analysts at Piper Jaffray. Analyst Christopher Raymond reiterated the firm's overweight rating on the North Chicago biopharma while increasing its price target to $92 from $90. At last check Tuesday AbbVie was trading down 1.2% at $86.
- Zacks
AbbVie (ABBV) Stock Moves -0.79%: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $87.04, moving -0.79% from the previous trading session.
